DARIOHEALTH CORP
DarioHealth Corp (DRIO) operates a digital health platform focused on chronic‑disease management, notably diabetes, combining a mobile app, connected devices and coaching to support patients and payers. With a market capitalisation around $51.25 million the company is a micro‑cap, which can offer upside if user growth and commercial partnerships scale, but also tends to experience higher volatility and financing risk. Investors should note limited scale, dependence on partnerships and the need for continued capital to expand programmes and RD. Key considerations include user engagement metrics, revenue per user, gross margin trends and cash runway; regulatory and competitive pressures in digital therapeutics are material. This summary is general educational information only, not personalised investment advice. Values can rise and fall, and past performance is not a guide to future returns. Prospective investors should review the company’s latest filings, quarterly updates and consult an authorised adviser about suitability for their portfolio.
Stock Performance Snapshot
Analyst Rating
Analysts recommend buying DarioHealth's stock with a target price of $5.67, indicating strong potential growth.
Financial Health
DarioHealth is showing strong revenue and cash flow, indicating solid financial performance.
View more stocks by downloading the app for FREE
It only takes 60 seconds.
Baskets Featuring DRIO
Wearable Health Stocks: Growth Potential vs Competition
Apple's recent FDA clearance for its Apple Watch hypertension feature marks a major step in wearable medical technology. This development opens up investment opportunities in the broader ecosystem of connected health devices and remote patient monitoring services.
Published: September 12, 2025
Explore BasketAt-Home Treatment Revolution | FDA Approval Impact
The FDA's approval of an injectable, at-home version of Eisai and Biogen's Alzheimer's drug signals a major shift in chronic disease management. This creates an investment opportunity in companies that develop advanced drug delivery systems and support at-home patient care.
Published: September 1, 2025
Explore BasketWearable Tech IP Wars: What Investors Should Know
Masimo's lawsuit against U.S. Customs, following a reversal of an import ban on Apple Watches, highlights the fierce competition over intellectual property in wearable health. This theme focuses on the medical technology companies and competitors poised to benefit from the ongoing patent battles in the lucrative health-monitoring device market.
Published: August 21, 2025
Explore BasketPharma's Digital Prescription
Novo Nordisk is partnering with GoodRx to offer its popular drug Ozempic at a reduced price, boosting GoodRx's stock. This collaboration highlights a growing trend of pharmaceutical companies leveraging digital health platforms to improve drug affordability and expand market reach.
Published: August 19, 2025
Explore BasketDigital Therapeutics & Prescription Apps
Software is becoming the new medicine. These carefully selected companies are developing FDA-cleared applications that treat everything from mental health to diabetes. With growing insurance reimbursement and massive scalability, these digital treatments represent healthcare's next frontier.
Published: June 17, 2025
Explore BasketDigital Therapeutics
Software that works like medicine. These companies are creating clinically validated digital tools that treat and manage diseases just like traditional pharmaceuticals, but with the scalability of technology. Professional investors see enormous potential in this rapidly evolving healthcare frontier.
Published: June 17, 2025
Explore BasketWhy You’ll Want to Watch This Stock
Digital chronic care
Platform for diabetes and other chronic conditions may scale via subscriptions and partnerships, though adoption and monetisation can vary.
Early-stage growth
Micro‑cap status signals potential room to grow but also reflects funding needs and above‑average share price volatility.
Partnerships & reach
Collaborations with payers and providers can drive distribution, while regulatory and competitive dynamics remain important risks.
Why invest with Nemo?
Zero Commission
Trade stocks, ETFs, and more with zero commission. Keep more of your returns.
Trusted & Regulated
Part of Exinity Group 2015, serving over a million customers globally.
6% Interest on Cash
Earn 6% AER on uninvested cash with daily interest payments.
Discover More Opportunities
Abbott Laboratories
Abbott Laboratories is a global healthcare company that develops and markets a broad range of health care products, including medical devices, diagnostics, nutritionals, and branded generic pharmaceuticals.
Agilent Technologies Inc.
Agilent Technologies, Inc. specializes in life sciences, diagnostics and applied markets, providing application-focused solutions that include instruments, software, services and consumables for the entire laboratory workflow. Its segments include Life Sciences and Diagnostics Markets, Agilent CrossLab and Applied Markets. Life Sciences and Diagnostics Markets segment comprises seven areas of activity. It offers active pharmaceutical ingredients for oligo-based therapeutics as well as solutions that include reagents, instruments, software and consumables. Agilent CrossLab segment offers a services and consumables portfolio that spans the entire lab, in addition to software and laboratory automation solutions, which are designed to enhance customer outcomes. Applied Markets segment offers application-focused solutions that include instruments and software that enable customers to identify, quantify and analyze the physical and biological properties of substances and products.
Align Technology Inc.
Align Technology is a medical device company that designs, manufactures and markets a range of dental and orthodontic products.
